Review on fungal enzyme inhibitors – potential drug targets to manage human fungal infections
暂无分享,去创建一个
T. Raman | Jayapradha Ramakrishnan | Sudarshan Singh Rathore | Thiagarajan Raman | S. S. Rathore | J. Ramakrishnan | Jayapradha Ramakrishnan
[1] C. Supuran,et al. Carbonic anhydrase inhibitors: inhibition of the β-class enzyme from the pathogenic yeast Candida glabrata with sulfonamides, sulfamates and sulfamides. , 2013, Bioorganic & medicinal chemistry letters.
[2] Shengzheng Wang,et al. Erg11 mutations associated with azole resistance in clinical isolates of Candida albicans. , 2013, FEMS yeast research.
[3] M. Rinaldi,et al. In Vitro Antifungal Activity of Nikkomycin Z in Combination with Fluconazole or Itraconazole , 1999, Antimicrobial Agents and Chemotherapy.
[4] J. Cleary,et al. Effect of Candida glabrata FKS1 and FKS2 Mutations on Echinocandin Sensitivity and Kinetics of 1,3-β-d-Glucan Synthase: Implication for the Existing Susceptibility Breakpoint , 2009, Antimicrobial Agents and Chemotherapy.
[5] D. Horn,et al. Factors related to survival and treatment success in invasive candidiasis or candidemia: a pooled analysis of two large, prospective, micafungin trials , 2010, European Journal of Clinical Microbiology & Infectious Diseases.
[6] Y. Koltin,et al. The search for new triazole antifungal agents. , 1997, Current opinion in chemical biology.
[7] M. Martín,et al. The use of fluconazole and itraconazole in the treatment of Candida albicans infections: a review. , 1999, The Journal of antimicrobial chemotherapy.
[8] D. Stevens,et al. Paradoxical Effect of Caspofungin: Reduced Activity against Candida albicans at High Drug Concentrations , 2004, Antimicrobial Agents and Chemotherapy.
[9] Duncan W. Wilson,et al. Candida albicans pathogenicity mechanisms , 2013, Virulence.
[10] C. Supuran. Structure-based drug discovery of carbonic anhydrase inhibitors , 2012, Journal of enzyme inhibition and medicinal chemistry.
[11] L. Harrison,et al. Declining Incidence of Candidemia and the Shifting Epidemiology of Candida Resistance in Two US Metropolitan Areas, 2008–2013: Results from Population-Based Surveillance , 2015, PloS one.
[12] T. C. White,et al. Azole Drug Import into the Pathogenic Fungus Aspergillus fumigatus , 2015, Antimicrobial Agents and Chemotherapy.
[13] P. O'Hara,et al. Molecular cloning, cDNA sequence, and bacterial expression of human glutamine:fructose-6-phosphate amidotransferase. , 1992, The Journal of biological chemistry.
[14] C. Supuran,et al. Drug Design of Zinc-Enzyme Inhibitors , 2009 .
[15] M. Arisawa,et al. A new methionine antagonist that has antifungal activity: mode of action. , 1994, The Journal of antibiotics.
[16] T. Osaki,et al. Lactoferrin Peptide Increases the Survival ofCandida albicans- Inoculated Mice by Upregulating Neutrophil and Macrophage Functions, Especially in Combination with Amphotericin B and Granulocyte-Macrophage Colony-Stimulating Factor , 2001, Infection and Immunity.
[17] S. Kelly,et al. Azole Resistance by Loss of Function of the Sterol Δ5,6-Desaturase Gene (ERG3) in Candida albicans Does Not Necessarily Decrease Virulence , 2012, Antimicrobial Agents and Chemotherapy.
[18] B. Posteraro,et al. Comparative Effects of Micafungin, Caspofungin, and Anidulafungin against a Difficult-To-Treat Fungal Opportunistic Pathogen, Candida glabrata , 2011, Antimicrobial Agents and Chemotherapy.
[19] S. Pöggeler,et al. Carbonic anhydrases in fungi. , 2010, Microbiology.
[20] D. Perlin. Echinocandin Resistance, Susceptibility Testing and Prophylaxis: Implications for Patient Management , 2014, Drugs.
[21] E. Borowski,et al. Glucosamine-6-phosphate synthase, a novel target for antifungal agents. Molecular modelling studies in drug design. , 2005, Acta biochimica Polonica.
[22] Martin Pouliot,et al. Pan Assay Interference Compounds (PAINS) and Other Promiscuous Compounds in Antifungal Research. , 2016, Journal of medicinal chemistry.
[23] C. Vigen,et al. Reduction of catheter-related bloodstream infections through the use of a central venous line bundle: epidemiologic and economic consequences. , 2011, American journal of infection control.
[24] A. Balaban,et al. Carbonic anhydrase inhibitors. Synthesis of 2,4,6-trimethylpyridinium derivatives of 2-(hydrazinocarbonyl)-3-aryl-1H-indole-5-sulfonamides acting as potent inhibitors of the tumor-associated isoform IX and XII. , 2009, Bioorganic & medicinal chemistry letters.
[25] K. Isono,et al. Studies on polyoxins, antifungal antibiotics. 13. The structure of polyoxins. , 1969, Journal of the American Chemical Society.
[26] R. Schwartz,et al. Discovery of Novel Antifungal (1,3)-β-d-Glucan Synthase Inhibitors , 2000, Antimicrobial Agents and Chemotherapy.
[27] B. Reinhold,et al. Architecture of the Yeast Cell Wall , 1997, The Journal of Biological Chemistry.
[28] Keshia M. Pollack,et al. The publics' understanding of daily caloric recommendations and their perceptions of calorie posting in chain restaurants , 2010, BMC public health.
[29] Alistair J. P. Brown,et al. Immune Recognition of Candida albicans β-glucan by Dectin-1 , 2007 .
[30] D. Perlin,et al. Correlating Echinocandin MIC and Kinetic Inhibition of fks1 Mutant Glucan Synthases for Candida albicans: Implications for Interpretive Breakpoints , 2008, Antimicrobial Agents and Chemotherapy.
[31] P. Smith,et al. Antifungal Therapy and Outcomes in Infants With Invasive Candida Infections , 2012, The Pediatric infectious disease journal.
[32] N. Gow,et al. Stimulation of Chitin Synthesis Rescues Candida albicans from Echinocandins , 2008, PLoS pathogens.
[33] D. Andes,et al. Pharmacodynamic Target Evaluation of a Novel Oral Glucan Synthase Inhibitor, SCY-078 (MK-3118), Using an In Vivo Murine Invasive Candidiasis Model , 2014, Antimicrobial Agents and Chemotherapy.
[34] Z. Hashemizadeh,et al. Opportunistic invasive fungal infections: diagnosis & clinical management , 2014, The Indian journal of medical research.
[35] D. Stevens,et al. Antifungal drug resistance. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[36] Russell E. Lewis,et al. Attenuation of the Activity of Caspofungin at High Concentrations against Candida albicans: Possible Role of Cell Wall Integrity and Calcineurin Pathways , 2005, Antimicrobial Agents and Chemotherapy.
[37] K. Hellingwerf,et al. Dynamics of cell wall structure in Saccharomyces cerevisiae. , 2002, FEMS microbiology reviews.
[38] S. Levick,et al. Community Composition and Abundance of Bacterial, Archaeal and Nitrifying Populations in Savanna Soils on Contrasting Bedrock Material in Kruger National Park, South Africa , 2016, Front. Microbiol..
[39] Zhenyu Zhu,et al. Enhancement of the antibiofilm activity of amphotericin B by polyamine biosynthesis inhibitors. , 2015, International journal of antimicrobial agents.
[40] M. Stolarska,et al. Synthesis, anticandidal activity of N(3)-(4-methoxyfumaroyl)-(S)-2,3-diaminopropanoic amide derivatives--novel inhibitors of glucosamine-6-phosphate synthase. , 2015, European journal of medicinal chemistry.
[41] P. L. McCormack. Isavuconazonium: First Global Approval , 2015, Drugs.
[42] Purification and characterization of a cytochrome P450 isozyme catalyzing lanosterol 14α-demethylation (P45014DM) in hamster liver , 1995, Lipids.
[43] E. Shuman,et al. Epidemiology of central nervous system infection. , 2012, Neuroimaging clinics of North America.
[44] Joseph Heitman,et al. Synergistic Antifungal Activities of Bafilomycin A1, Fluconazole, and the Pneumocandin MK-0991/Caspofungin Acetate (L-743,873) with Calcineurin Inhibitors FK506 and L-685,818 against Cryptococcus neoformans , 2000, Antimicrobial Agents and Chemotherapy.
[45] F. Botterel,et al. Contribution of (1,3)-Beta-d-Glucan to Diagnosis of Invasive Candidiasis after Liver Transplantation , 2014, Journal of Clinical Microbiology.
[46] D. Loebenberg,et al. Three-Dimensional Models of Wild-Type and Mutated Forms of Cytochrome P450 14α-Sterol Demethylases from Aspergillus fumigatus and Candida albicans Provide Insights into Posaconazole Binding , 2004, Antimicrobial Agents and Chemotherapy.
[47] R. Tovar,et al. Meningitis due to Cryptococcus neoformans: treatment with posaconazole. , 2012, Current HIV research.
[48] J. Perfect,et al. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[49] C. Supuran,et al. Drug design of Zinc-enzyme inhibitors: functional, structural and disease applications , 2009 .
[50] C. Steegborn,et al. CO2 Acts as a Signalling Molecule in Populations of the Fungal Pathogen Candida albicans , 2010, PLoS pathogens.
[51] Suresh Kumar,et al. In-vitro antimicrobial screening and molecular docking studies of synthesized 2-chloro-N-(4-phenylthiazol-2-yl)acetamide derivatives , 2015 .
[52] F. Barchiesi,et al. In-vitro interaction of terbinafine with amphotericin B, fluconazole and itraconazole against clinical isolates of Candida albicans. , 1998, The Journal of antimicrobial chemotherapy.
[53] M. Arendrup,et al. Acquired antifungal drug resistance in Aspergillus fumigatus: epidemiology and detection. , 2011, Medical mycology.
[54] J. Perfect,et al. Use of Antifungal Combination Therapy: Agents, Order, and Timing , 2010, Current fungal infection reports.
[55] S. Alper,et al. Inhibition of Ca(2+)-dependent K+ transport and cell dehydration in sickle erythrocytes by clotrimazole and other imidazole derivatives. , 1993, The Journal of clinical investigation.
[56] S. Silverman,et al. The function of chitin synthases 2 and 3 in the Saccharomyces cerevisiae cell cycle , 1991, The Journal of cell biology.
[57] Sergey V. Balashov,et al. Assessing Resistance to the Echinocandin Antifungal Drug Caspofungin in Candida albicans by Profiling Mutations in FKS1 , 2006, Antimicrobial Agents and Chemotherapy.
[58] M. Pfaller,et al. Effects of cilofungin (LY121019) on carbohydrate and sterol composition ofCandida albicans , 1989, European Journal of Clinical Microbiology and Infectious Diseases.
[59] G. Gece. Drugs: A review of promising novel corrosion inhibitors , 2011 .
[60] N. Greer. Voriconazole: The Newest Triazole Antifungal Agent , 2003, Proceedings.
[61] R. Jedrzejczak,et al. Amide and ester derivatives of N3-(4-methoxyfumaroyl)-(S)-2,3-diaminopropanoic acid: the selective inhibitor of glucosamine-6-phosphate synthase. , 2001, Bioorganic & medicinal chemistry.
[62] R. Cannon,et al. Overexpression of Candida albicans CDR1, CDR2, or MDR1 Does Not Produce Significant Changes in Echinocandin Susceptibility , 2006, Antimicrobial Agents and Chemotherapy.
[63] John R Perfect,et al. Resistance to Antifungal Agents: Mechanisms and Clinical Impact , 2008 .
[64] Ivone M. Martins,et al. Differential Activities of Three Families of Specific β(1,3)Glucan Synthase Inhibitors in Wild-type and Resistant Strains of Fission Yeast* , 2010, The Journal of Biological Chemistry.
[65] J. Heitman,et al. Carbonic Anhydrase and CO2 Sensing during Cryptococcus neoformans Growth, Differentiation, and Virulence , 2005, Current Biology.
[66] K. Kakiki,et al. STUDIES ON THE MODE OF ACTION OF POLYOXINS. VI , 1974 .
[67] Miguel C. Teixeira,et al. Candida glabrata Drug:H+ Antiporter CgQdr2 Confers Imidazole Drug Resistance, Being Activated by Transcription Factor CgPdr1 , 2013, Antimicrobial Agents and Chemotherapy.
[68] S. A. Parent,et al. Specific Substitutions in the Echinocandin Target Fks1p Account for Reduced Susceptibility of Rare Laboratory and Clinical Candida sp. Isolates , 2005, Antimicrobial Agents and Chemotherapy.
[69] Kana Matsumoto,et al. Chronic invasive sinus and intracerebral aspergillosis controlled by combination therapy with micafungin and a daily dose of 400 mg itraconazole oral solution. , 2015, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.
[70] M. Pfaller,et al. Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. , 2012, The American journal of medicine.
[71] P. Klein,et al. Leucine oxidation changes rapidly after dietary protein intake is altered in adult women but lysine flux is unchanged as is lysine incorporation into VLDL-apolipoprotein B-100. , 1994, The Journal of nutrition.
[72] Alistair J. P. Brown,et al. The PKC, HOG and Ca2+ signalling pathways co‐ordinately regulate chitin synthesis in Candida albicans , 2007, Molecular microbiology.
[73] D. Kontoyiannis,et al. Caspofungin-Resistant Candida tropicalis Strains Causing Breakthrough Fungemia in Patients at High Risk for Hematologic Malignancies , 2008, Antimicrobial Agents and Chemotherapy.
[74] J. Smith,et al. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872) , 1997, Antimicrobial agents and chemotherapy.
[75] C. Supuran,et al. Carbonic anhydrase inhibitors. Inhibition of the fungal beta-carbonic anhydrases from Candida albicans and Cryptococcus neoformans with boronic acids. , 2009, Bioorganic & medicinal chemistry letters.
[76] C. Supuran,et al. Carbonic anhydrase inhibitors. Inhibition and homology modeling studies of the fungal beta-carbonic anhydrase from Candida albicans with sulfonamides. , 2009, Bioorganic & medicinal chemistry.
[77] P. Gopal,et al. Evidence for a glycosidic linkage between chitin and glucan in the cell wall of Candida albicans. , 1988, Journal of general microbiology.
[78] C. Supuran,et al. In-vitro antibacterial, antifungal and cytotoxic properties of sulfonamide—derived Schiff's bases and their metal complexes , 2005, Journal of enzyme inhibition and medicinal chemistry.
[79] S. Kelly,et al. Itraconazole resistance in Aspergillus fumigatus , 1997, Antimicrobial agents and chemotherapy.
[80] C. Supuran,et al. Carbonic anhydrase inhibitors. Inhibition of the β-class enzymes from the fungal pathogens Candida albicans and Cryptococcus neoformans with branched aliphatic/aromatic carboxylates and their derivatives. , 2011, Bioorganic & medicinal chemistry letters.
[81] E. Borowski,et al. Antihistoplasmal in vitro and in vivo effect of Lys-Nva-FMDP. , 1998, Medical mycology.
[82] N. Gow,et al. Fungal echinocandin resistance , 2010, Fungal genetics and biology : FG & B.
[83] T. Raman,et al. Magnesium Ion Acts as a Signal for Capsule Induction in Cryptococcus neoformans , 2016, Front. Microbiol..
[84] R. Andruszkiewicz,et al. Antifungal activity of thionated analogues of Nva-FMDP and Lys-Nva-FMDP. , 2009, Polish journal of microbiology.
[85] J. Donnelly. Polymerase chain reaction for diagnosing invasive aspergillosis: getting closer but still a ways to go. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[86] B. Posteraro,et al. Antifungal drug resistance among Candida species: mechanisms and clinical impact , 2015, Mycoses.
[87] W. Sly,et al. Structure, function and applications of carbonic anhydrase isozymes. , 2013, Bioorganic & medicinal chemistry.
[88] S. Jaffar,et al. Short course amphotericin B with high dose fluconazole for HIV-associated cryptococcal meningitis. , 2012, The Journal of infection.
[89] D. Sheehan,et al. Current and Emerging Azole Antifungal Agents , 1999, Clinical Microbiology Reviews.
[90] Cynthia T. Nguyen,et al. Role of New Antifungal Agents in the Treatment of Invasive Fungal Infections in Transplant Recipients: Isavuconazole and New Posaconazole Formulations , 2015, Journal of fungi.
[91] A. Barnes,et al. Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance. , 2002, The Journal of hospital infection.
[92] Gerard D. Wright,et al. Identification and Characterization of New Inhibitors of Fungal Homoserine Kinase , 2011, Chembiochem : a European journal of chemical biology.
[93] R. Kaneno,et al. Paracoccidioides brasiliensis Interferes on Dendritic Cells Maturation by Inhibiting PGE2 Production , 2015, PloS one.
[94] D. Perlin. Mechanisms of echinocandin antifungal drug resistance , 2015, Annals of the New York Academy of Sciences.
[95] P. Carver,et al. Comparison of echinocandin antifungals , 2007, Therapeutics and clinical risk management.
[96] F. Meunier,et al. In-vitro activity of cilofungin (LY121019) in comparison with amphotericin B. , 1989, Journal of Antimicrobial Chemotherapy.
[97] I. Gabriel,et al. Inhibitors of amino acids biosynthesis as antifungal agents , 2014, Amino Acids.
[98] K. Hellingwerf,et al. Molecular organization of the cell wall of Candida albicans. , 2001, Medical mycology.
[99] Alan S. Perelson,et al. High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men , 2010, PLoS pathogens.
[100] Yanxia Shi,et al. Design, Synthesis and Bioactivity of Novel Glycosylthiadiazole Derivatives , 2014, Molecules.
[101] A. Velegraki,et al. Saccharomyces boulardii fungaemia in an intensive care unit patient treated with caspofungin , 2008, Critical care.
[102] A. Onderdonk,et al. Effect of Candida albicans Infection and Clotrimazole Treatment on Vaginal Microflora In Vitro , 1995, Obstetrics and gynecology.
[103] D. Falci,et al. Profile of isavuconazole and its potential in the treatment of severe invasive fungal infections , 2013, Infection and drug resistance.
[104] K. Kaila,et al. Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. , 2010, Journal of medicinal chemistry.
[105] C. Clancy,et al. Paradoxical Effect of Caspofungin against Candida Bloodstream Isolates Is Mediated by Multiple Pathways but Eliminated in Human Serum , 2011, Antimicrobial Agents and Chemotherapy.
[106] J. Lopez-Ribot,et al. In Vitro Activity of Caspofungin (MK-0991) against Candida albicans Clinical Isolates Displaying Different Mechanisms of Azole Resistance , 2002, Journal of Clinical Microbiology.
[107] K. Garey,et al. Echinocandin Resistance in Candida Species: Mechanisms of Reduced Susceptibility and Therapeutic Approaches , 2012, The Annals of pharmacotherapy.
[108] P. Cos,et al. Artemisinins, New Miconazole Potentiators Resulting in Increased Activity against Candida albicans Biofilms , 2014, Antimicrobial Agents and Chemotherapy.
[109] P. Williamson,et al. Role of Homoserine Transacetylase as a New Target for Antifungal Agents , 2007, Antimicrobial Agents and Chemotherapy.
[110] W. Melchers,et al. Failure of Posaconazole Therapy in a Renal Transplant Patient with Invasive Aspergillosis Due to Aspergillus fumigatus with Attenuated Susceptibility to Posaconazole , 2011, Antimicrobial Agents and Chemotherapy.
[111] L. Cowen,et al. Regulatory Circuitry Governing Fungal Development, Drug Resistance, and Disease , 2011, Microbiology and Molecular Reviews.
[112] Jaqueline Moisés Tobal,et al. Role of carbonic anhydrases in pathogenic micro-organisms: a focus on Aspergillus fumigatus. , 2014, Journal of medical microbiology.
[113] S. Milewski. Glucosamine-6-phosphate synthase--the multi-facets enzyme. , 2002, Biochimica et biophysica acta.
[114] Claudiu T. Supuran,et al. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators , 2008, Nature Reviews Drug Discovery.
[115] J. Mccusker,et al. Cryptococcus neoformans Ilv2p confers resistance to sulfometuron methyl and is required for survival at 37 °C and in vivo , 2004 .
[116] R. J. Herr,et al. Discovery of a Novel Class of Orally Active Antifungal β-1,3-d-Glucan Synthase Inhibitors , 2011, Antimicrobial Agents and Chemotherapy.
[117] L. Mutter,et al. Efinaconazole: Developmental and reproductive toxicity potential of a novel antifungal azole. , 2015, Reproductive toxicology.
[118] Y. Barenholz,et al. Efficacy Evaluation of a Novel Submicron Miconazole Emulsion in a Murine Cryptococcosis Model , 1995, Pharmaceutical Research.
[119] P. Robbins,et al. Architecture of the Yeast Cell Wall , 1995, The Journal of Biological Chemistry.
[120] A. Armaganidis,et al. Invasive Fungal Infections in the ICU: How to Approach, How to Treat , 2014, Molecules.
[121] Toru Nakai,et al. Synthesis and antifungal activity of ASP9726, a novel echinocandin with potent Aspergillus hyphal growth inhibition. , 2014, Bioorganic & medicinal chemistry letters.
[122] C. Supuran,et al. Structure and inhibition of the CO2-sensing carbonic anhydrase Can2 from the pathogenic fungus Cryptococcus neoformans. , 2008, Journal of molecular biology.
[123] D. Kelly,et al. Azole Affinity of Sterol 14α-Demethylase (CYP51) Enzymes from Candida albicans and Homo sapiens , 2012, Antimicrobial Agents and Chemotherapy.
[124] J. Tkacz,et al. The fungal cell wall as a drug target. , 1995, Trends in microbiology.
[125] E. Anaissie,et al. Factors associated with mortality in transplant patients with invasive aspergillosis. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[126] E. Borowski. Novel approaches in the rational design of antifungal agents of low toxicity. , 2000, Farmaco.
[127] D. Kontoyiannis,et al. The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer. , 2002, The American journal of medicine.
[128] T. Walsh,et al. Activities of Triazole-Echinocandin Combinations against Candida Species in Biofilms and as Planktonic Cells , 2011, Antimicrobial Agents and Chemotherapy.
[129] M. Cuenca-Estrella,et al. Importancia clínica de los mecanismos de resistencia de los hongos filamentosos a los antifúngicos , 2002 .
[130] E. Borowski,et al. A diffusible analogue of N(3)-(4-methoxyfumaroyl)-L-2,3-diaminopropanoic acid with antifungal activity. , 2001, Microbiology.
[131] M. Shivaprakash,et al. Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study , 2010, Bone Marrow Transplantation.
[132] C. Supuran. Inhibition of carbonic anhydrase from Trypanosoma cruzi for the management of Chagas disease: an underexplored therapeutic opportunity. , 2016, Future medicinal chemistry.
[133] N. Gow,et al. Elevated Cell Wall Chitin in Candida albicans Confers Echinocandin Resistance In Vivo , 2011, Antimicrobial Agents and Chemotherapy.